Analysis of 11C-methionine uptake in low-grade gliomas and correlation with proliferative activity

American Journal of Neuroradiology

Volumn 29, Issue 10, 2008, Pages 1867-1871

  Kato, Takayuki ^a,b   Shinoda, J ^a   Oka, N ^a   Miwa, K ^a   Nakayama, N ^b   Yano, H ^b   Maruyama, T ^c   Muragaki, Y ^c   Iwama, T ^b  

^a Kizawa Memorial Hospital   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; METHIONINE C 11; CARBON; DIAGNOSTIC AGENT; METHIONINE; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; ASTROCYTOMA; CANCER DIAGNOSIS; CELL PROLIFERATION; CLINICAL ARTICLE; DRUG UPTAKE; FEMALE; GLIOMA; HUMAN; MALE; MALIGNANT TRANSFORMATION; OLIGODENDROGLIOMA; POSITRON EMISSION TOMOGRAPHY; TUMOR GROWTH; BRAIN TUMOR; CANCER INVASION; METABOLISM; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STATISTICS;

ADULT; BRAIN NEOPLASMS; CARBON RADIOISOTOPES; FEMALE; GLIOMA; HUMANS; MALE; METHIONINE; NEOPLASM INVASIVENESS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC;

EID: 56849084134     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: 10.3174/ajnr.A1242     Document Type: Article

References (32)

1. Herholz K, Coope D, Jackson A. Metabolic and molecular imaging in neurooncology. Lancet Neurol 2007;6:711-24
2. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: The EORTC 22845 randomised trial. Lancet 2005;366:985-90
3. Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103:802-09
4. Whittle IR. The dilemma of low grade glioma. J Neurol Neurosurg Psychiatry 2004;75 Suppl 2:ii31-36
5. Wessels PH, Weber WE, Raven G, et al. Supratentorial grade II astrocytoma: Biological features and clinical course. Lancet Neurol 2003;2:395-403
6. Goldman S, Wikler D, Damhaut P, et al. Positron emission tomography and brain tumours. Acta Neurol Belg 1997;97:183-86
7. Di Chiro G, DeLaPaz RL, Brooks RA, et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323-29
8. Ogawa T, Inugami A, Hatazawa J, et al. Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl-11C-methionine. AJNR Am J Neuroradiol 1996;17:345-53
9. Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995;195:47-52
10. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778-85
11. Bustany P, Chatel M, Derlon JM, et al. Brain tumor protein synthesis and histological grades: a study by positron emission tomography (PET) with C11-L-methionine. J Neurooncol 1986;3:397-404
12. Derlon JM, Bourdet C, Bustany P, et al. [11C]L-methionine uptake in gliomas. Neurosurgery 1989;25:720-28
13. Herholz K, Holzer T, Bauer B, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998;50:1316-22
14. De Witte O, Goldberg I, Wikler D, et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 2001;95:746-50
15. Kim S, Chung JK, Im SH, et al. 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 2005;32:52-59
16. Sato N, Suzuki M, Kuwata N, et al. Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev 1999;22:210-14
17. Ribom D, Eriksson A, Hartman M, et al. Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. Cancer 2001;92:1541-49
18. Kracht LW, Friese M, Herholz K, et al. Methyl-[11C]-L-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 2003;30:868-73
19. Smits A, Westerberg E, Ribom D. Adding (11)C-methionine PET to the EORTC prognostic factors in grade 2 gliomas. Eur J Nucl Med Mol Imaging 2008;35:65-71
20. Louis DN, Ohgaki H, Wiestler OD, et al. WHO classification of tumours of the central nervous system (2007). Lyon, France: IARC 2007
21. Miwa K, Shinoda J, Yano H, et al. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry 2004;75:1457-62
22. Derlon JM, Petit-Taboué MC, Chapon F, et al. The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine. Neurosurgery 1997;40: 276-87; discussion 287-88
23. Cha S, Tihan T, Crawford F, et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2005;26:266-73
24. Vertosick FT Jr, Selker RG, Arena VC. Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography. Neurosurgery 1991;28:496-501
25. McCormack BM, Miller DC, Budzilovich GN, et al. Treatment and survival of low-grade astrocytoma in adults-1977-1988. Neurosurgery 1992;31:636-42; discussion 642
26. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol. 1999;1:44-51
27. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170:1445-53
28. Langen KJ, Mühlensiepen H, Holschbach M, et al. Transport mechanisms of 3-[123I]iodo-alpha-methyl-L-tyrosine in a human glioma cell line: comparison with [3H]methyl]-L-methionine. J Nucl Med 2000;41:1250-55
29. Bergstrom M, Ericson K, Hagenfeldt L, et al. PET study of methionine accumulation in glioma and normal brain tissue: competition with branched chain amino acids. J Comput Assist Tomogr 1987;11:208-13
30. Killian DM, Chikhale PJ. Predominant functional activity of the large, neutral amino acid transporter (LAT1) isoform at the cerebrovasculature. Neurosci Lett 2001;306:1-4
31. Miyagawa T, Oku T, Uehara H, et al. "Facilitated" amino acid transport is upregulated in brain tumors J Cereb Blood Flow Metab 1998;18:500-09
32. Roelcke U, Radü E, Ametamey S, et al. Association of rubidium and C-methionine uptake in brain tumors measured by positron emission tomography. J Neurooncol 1996;27:163-71